MAPT and dementia: Currently, 55 million people worldwide are affected by dementia, with AD being the cause in approximately three out of four cases.1 Nowadays, biomarkers such as amyloid-β (Aβ) or neurofibrillary tangles (tau) can detect AD years before clinical manifestation.2,3 This provides a window of opportunity to prevent or slow down disease progression prior to the onset of dementia.4 There is no one-size-fits-all approach to the diagnosis, prediction, and prevention of AD, as individuals differ in their preferences, needs, and wishes.